Abstract: Warfarin is a common anticoagulant drug in clinic. But its clinical use is limited because of its narrow therapeutic window, slow onset of anticoagulant and the effects are impacted easily by drug and food. So it will improve clinical safety and effectiveness of warfarin through establishing a new individualized warfarin dosing regimen based on pharmacogenomics. An authority model recommended by FDA is The International Warfarin Pharmacogenetics Consortium model in America and Europe. But whether it will apply to the Chinese population or not is inconclusive. Many models of Asian population were proposed, but the study sample size is too small to be representative. China has established a research of multi-center and large sample recently, which is expected to establish a model of our population and applied to our clinical.

Key words: Warfarin, pharmacogenomics, individualized administration, algorithms, advance